Anzeige
Mehr »
Dienstag, 10.02.2026 - Börsentäglich über 12.000 News
Goldman sieht 15.000 USD bei Kupfer - dieser Explorer ist noch völlig unbekannt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
146 Leser
Artikel bewerten:
(0)

New Reproductive Support Dietary Supplement, Pregnitude', Now Available For Women Having Difficulty Conceiving

WEST ORANGE, N.J., May 7, 2012 /PRNewswire/ -- A new non-prescription Reproductive Support Dietary Supplement, Pregnitude', which contains myo-inositol (2 g), plus folic acid (200 mcg), is now available for women who are having difficulty conceiving, Everett Laboratories announced today.In clinical studies, Pregnitude has been shown to help support ovulation function and menstrual cycle regularity as well as support the quality of a woman's eggs.

"Everett Labs is proud to make this new, important contribution to women's health.With Pregnitude, we're thrilled to provide a new option to support women who are having difficulty conceiving.We are confident that obstetricians and gynecologists around the country will find this a valuable alternative for women to support the ovulation frequency, regularity and quality of eggs," said Lucas Sigman, Chief Executive Officer, Everett Laboratories, Inc.

Myo-inositol is a naturally occurring substance produced in the human body that belongs to the vitamin B complex group and is found naturally in many foods such as fruits, cereals with high bran content, nuts and beans.Both myo-inositol and folic acid are considered to be important nutrients for women who are trying to become pregnant.

Approximately 6.1 million women in the United States have difficulty getting pregnant, according to the Centers for Disease Control and Prevention (CDC).

"There is a tremendous need for support of couples having difficulty conceiving.They're often left frustrated and anxious, and the stress can compound the problem.Pregnitude can help support ovulation function, menstrual cycle regularity, and quality of eggs during this difficult time," said Scott Eder, M.D., Medical Director, Everett Laboratories and a board-certified obstetrician and gynecologist who practices in Lawrenceville, NJ.

Pregnitude is a powder formulation that is mixed with water and taken twice a day, in the morning and evening. It is available without a prescription at most major retail pharmacies and can be found behind the pharmacy counter.Consumers can also order Pregnitude online, at www.pregnitude.com.

Clinical Trials with Myo-inositol in Combination with Folic Acid

Controlled clinical studies have demonstrated that supplementation with myo-inositol has a beneficial effect on ovulatory function, improving ovulation frequency, promoting menstrual cycle regularity and improving the quality of oocytes, or immature eggs.

"The results of the clinical trials with myo-inositol supplementation are particularly encouraging in supporting ovarian function.We are thrilled to provide another tool to support women wishing to become pregnant," said Dr. Eder.

Side effects and Who Should Not Use Pregnitude

Pregnitude is generally well tolerated.Women may experience gastrointestinal effects such as nausea and diarrhea when taken at high doses. Pregnitude should not be taken by anyone with a known hypersensitivity to either myo-inositol or folic acid.Folic acid should not be taken by anyone with untreated or uncomplicated pernicious anemia and those with anaphylactic sensitivity to folic acid.In addition, high doses of myo-inositol may have additive effects when taken concurrently with selective serotonin reuptake inhibitor (SSRI) and selective serotonin norepinephrine reuptake inhibitor (SNRI) antidepressant medications.Women who take these medications should talk to their doctor before using Pregnitude.

About Everett Laboratories, Inc.

Everett Laboratories Inc. is a New Jersey-based women's healthcare pharmaceutical company that has been providing essential pharmaceutical and nutritional products for four decades. Everett Laboratories Inc. is a subsidiary of The Chemo Group, a global healthcare corporation based in Spain with a presence in more than 30 countries.The company recently licensed products for stress urinary incontinence, fertility, and the Stuart Natal line of pre-natal vitamins.Everett Laboratories Inc. is dedicated to providing advanced treatments and innovative new products to address unmet needs for women and families and to improving women's health.The company strives to produce and market unique, first-in-class prescription and over the counter medications.

SOURCE Everett Laboratories, Inc.

© 2012 PR Newswire
Vorsicht, geheim!
2026 startet mit einem Paukenschlag: Der DAX outperformt den US-Markt, Nachzügler holen auf. Ein erstes Signal, dass der Bullenmarkt an Breite gewinnt. Während viele Anleger weiter auf die großen Tech-Namen setzen, hat sich im Hintergrund längst ein Umschwung vollzogen. Der Fokus verschiebt sich weg von überteuerten KI-Highflyern hin zu soliden Qualitätswerten aus der zweiten Reihe.

Anleger, die jetzt clever agieren, setzen nicht auf das, was war, sondern auf das, was kommt. Unternehmen mit gesunder Bilanz, unterschätztem Potenzial und begrenztem Abwärtsrisiko könnten 2026 zu den großen Gewinnern zählen. Die Gefahr einer schärferen Korrektur bleibt real, gerade für passiv aufgestellte Investoren.

In unserem neuen Spezialreport stellen wir fünf Aktien vor, die genau jetzt das Potenzial für überdurchschnittliche Renditen bieten. Stark, günstig und bislang kaum im Fokus.

Jetzt kostenlosen Report herunterladen – bevor es andere tun!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.